ReviewCell reports. Medicine2025
Addressing clinical needs in NSCLC immunotherapy: Mechanisms of resistance and promising combination strategies.
Review in Cell reports. Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it.
- EML4-ALK in Non-small Cell Lung Cancer: Molecular Mechanisms and Targeted Therapies.Technology in cancer research & treatmentPooled it
- Improving neoadjuvant and perioperative therapy in non-small-cell lung cancer.Nature reviews. Clinical oncology · 2026Review
- Immune Regulation and the Role of Extracellular Vesicles in Non-Small Cell Lung Cancer: Biological Mechanisms and Therapeutic Perspectives.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Single-cell transcriptomic analysis identifies a tumor-enriched GIMAP7⁺ CD4⁺ naïve T cell population with a unique immunoregulatory state in lung adenocarcinoma.Functional & integrative genomics · 2026Article
- Regulatory B-cell states in NSCLC immunotherapy resistance: mechanisms, spatial context and translational implications.Cancer immunology, immunotherapy : CII · 2026Review
- Multidrug resistance in cancer: current understandings and future perspective.Molecular biomedicine · 2026Review
- Article
- From Mechanisms to Therapeutic Innovation in Non-Small Cell Lung Cancer: A Knowledge-Depth Translational Mapping with Experimental Validation.International journal of molecular sciences · 2026Article
- A Roadmap to Transform Lung Cancer Outcomes: Priorities in Biology, Therapeutic Innovation, Early Detection, Prevention, and Interception.Cancer discovery · 2026Review
- Targeting oncogenic NTSR1 with liensinine reprograms Gq-mediated signaling to suppress lung adenocarcinoma.Chinese medicine · 2026Article
- Immunotherapy rechallenge in gastric cancer: resistance mechanisms, molecular stratification, and precision decision-making.Frontiers in immunology · 2026Review
- Real-world outcomes and safety of inetetamab plus pyrotinib and chemotherapy in HER2-positive metastatic breast cancer: A multicenter retrospective study.Therapeutic advances in medical oncology · 2026Article
- Exploring traditional Chinese medicine to enhance the efficacy and reduce toxicity of immunotherapy for non-small cell lung cancer from the perspective of "spleen deficiency": a trial protocol for mechanism and clinical evidence.Frontiers in oncology · 2026Article
- Patient-derived organoids (PDOs): a novel preclinical platform to overcome challenges in cancer immunotherapy.Frontiers in cell and developmental biology · 2026Review
- Digital immune twins and ai-integrated multi-omic biomarkers: Redefining personalized immunotherapy in non-small cell lung cancer.Iranian journal of basic medical sciences · 2026Review
- Editorial: Biomarker-guided strategies in NSCLC immunotherapy.Frontiers in oncology · 2025Article
- Pharmacological strategies to overcome immune checkpoint inhibitor resistance in non-small cell lung cancer.Frontiers in oncology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PD-(L)1 monoclonal antibody-based immunotherapy has become the cornerstone of treatment for non-small cell lung cancer without driver gene alterations. However, resistance, including primary and acquired resistance, remains a major clinical challenge. In this review, we summarize the delayed separation of progression-free survival curves observed in randomized clinical trials, which reflects the emergence of resistance at different treatment stages and the dynamic evolution of anti-tumor immune responses. The development of effective combination strategies should therefore be guided by a thorough understanding of the complex biological mechanisms governing tumor-immune interactions. We review the underlying mechanisms of immunotherapy resistance and propose potential combination strategies. Finally, we emphasize several key considerations for future clinical trial design, including the sequencing of combination therapies, biomarker-guided treatment selection, and optimized management of treatment-related toxicities.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.